Redx Pharma “setting the bar” with next generation drugs

Redx Pharma “setting the bar” with next generation drugs

Redx Pharma Plc CEO Neil Murray talks about the progress the drug discovery firm has made since the IPO in March.

“I would like to say we are setting the bar, rather than playing catch-up…we are very much pushing the boundaries,” he said. Talking about the group’s MRSA programme in particular “We have produced the first new class of drugs in a generation – there hasn’t been a new class of antibiotics in about twenty years. That is a huge step forward in the fight against resistant infection,” he said. See

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.